SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
A biopharma with 54% upside, with or without M&A - Evercore
seekingalpha · 4d ago
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 5d ago
Why Principia Could Be the Next Target of Sanofi's Makeover
Buyout rumors have spurred a sharp increase in the small biotech’s shares Continue reading...
GuruFocus.com · 07/19 15:11
64 Biggest Movers From Yesterday
Gainers InnerWorkings, Inc. (NASDAQ: INWK) shares jumped 115.9% to close at $2.85 on Thursday after HH Global announced plans to acquire the company for $3 per share.
Benzinga · 07/17 09:08
Sanofi Considers U.S. Biotech Targets Including Principia
(Bloomberg) -- Sanofi is studying potential acquisitions of U.S. biotechnology companies including Principia Biopharma Inc. as it seeks innovative treatments for clinical areas including multiple sclerosis and immune disorders, people with knowledge of the mat
Bloomberg · 07/17 08:13
Principia Biopharma Soars as Sanofi Is Said to Seek Deals
Sanofi is reportedly looking at potential acquisitions of U.S. biotechs. Principia Biopharma shares jumped on the report.
TheStreet.com · 07/16 19:52
Sanofi Said To Study U.S. Biotech Targets Including Principa; Said To Work With Advisers To Consider Potential Deals
Bloomberg · 07/16 17:30
Principia Biopharma (PRNB) Jumps: Stock Rises 6.8%
Principia Biopharma (PRNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Zacks · 07/16 12:42
The Daily Biotech Pulse: Mallinckrodt Gets FDA Panel Backing, Regulatory Setback For Tricida, Relay Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 07/16 12:31
Guggenheim Initiates Coverage On Principia Biopharma with Buy Rating, Announces Price Target of $100
Guggenheim initiates coverage on Principia Biopharma (NASDAQ:PRNB) with a Buy rating and announces Price Target of $100.
Benzinga · 07/06 11:41
Principia Announces First Patient Enrolled in Sanofi's Phase 3 Trial of SAR442168 in Relapsing MS
Principia Biopharma Inc. (NASDAQ: PRNB) today announced that the first patient has been enrolled in its partner Sanofi's Phase 3 clinical trial of SAR442168 in patients with relapsing multiple sclerosis (RMS). Upon dosing, Principia will be entitled to a $
Benzinga · 06/23 09:46
Principia Announces First Patient Enrolled in Sanofis Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis
GlobeNewswire · 06/23 06:15
Hedge Funds Have Never Been This Bullish On Principia Biopharma Inc. (PRNB)
Insider Monkey · 06/18 20:07
Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus
GlobeNewswire · 06/12 21:05
Principia's rilzabrutinib shows positive effect in rare skin-blistering disorder
Seeking Alpha - Article · 06/12 20:26
Principia Announces Data From Phase 2 Part B Trial In Pemphigus
Clear dose-response combined with decreased daily corticosteroid usage Response rate increased with extended duration of treatment to six months while maintaining a favorable safety profile SOUTH SAN FRANCISCO, Calif.,
Benzinga · 06/12 20:05
Principia's rilzabrutinib shows positive response in immune thrombocytopenia
Seeking Alpha - Article · 06/12 13:43
Principia Biopharma Highlights Presentation Of Updated Positive Data Of Rilzabrutinib For Immune Thrombocytopenia In Ongoing Phase 1/2 Trial
Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced positive data on durability of response from an ongoing Phase
Benzinga · 06/12 10:10
Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
A total of 47 heavily pre-treated patients (median of six prior therapies) with immune thrombocytopenia (ITP) have been enrolled with a median follow-up of 18 weeks. Data from this trial are being presented by David Kuter, M.D., director of Clinical Hematolog
GlobeNewswire · 06/12 10:05
The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage
Benzinga · 06/07 18:43